PUBLIC COMPANY
save$KALVKalVista Pharmaceuticals, Inc.
$KALVFramingham, MA, USupdated 2mo ago
community read0 votes
pipeline
1
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase4Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)
- phase3An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
- —Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat
- phase3Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
- —A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
- —Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat
- phase3PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
- phase3A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Insider activity
source: SEC Form 4open-market buys + sells
routine RSU / option mechanics (6)
- Apr 16, 26option exerciseSweeny Nicole · Chief Commercial Officer6,250 sh
- Apr 16, 26option exercisePiekos Brian · Chief Financial Officer6,250 sh
- Apr 16, 26option exercisePiekos Brian · Chief Financial Officer6,250 sh
- Apr 16, 26option exercisePalleiko Benjamin L · CHIEF EXECUTIVE OFFICER20,312 sh
- Apr 16, 26option exercisePalleiko Benjamin L · CHIEF EXECUTIVE OFFICER20,312 sh
- Apr 16, 26option exerciseAudhya Paul K. · CHIEF MEDICAL OFFICER6,250 sh
🐶 Hiring Signal
News
- Chiesi signs $1.9B deal to acquire KalVista and its approved drugChiesi is buying commercial biotech KalVista Pharmaceuticals for about $1.9 billion in an extension of the industry's vigorous spring shopping spree. The Italian pharma will pay $27 per share {$KAL…endpoints · 5mo ago
Data sources
last refreshed 57m ago
Found something off?
comments(0)
5-min edit window · permanent after that